A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma

A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 51, Issue 13, September 2015, Pages 1794-1802

Elizabeth J. Davis, Rashmi Chugh, Lili Zhao, David R. Lucas, J. Sybil Biermann, Mark M. Zalupski, Mary Feng, Sandra L. Wong, Jon Jacobson, Laurie Zyczynski, Denise Reinke, Gino Metko, Laurence H. Baker, Scott M. Schuetze,